

HOXA11-AS: a novel regulator in human cancer proliferation and metastasis

Jiang-yang Xue¹
Chao Huang²
Wei Wang¹
Hai-bo Li¹
Ming Sun³
Min Xie²

¹Center for Reproduction and Genetics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, China; ²Central Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, China; ³Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX, USA

Correspondence: Min Xie
Central Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, 26 Daoqian Street, Suzhou, Jiangsu Province 215002, China
Tel +86 0512 6236 2417
Email xmszsl90@163.com

Ming Sun
Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, USA
Tel +1 713 792 8856
Email msun7@mdanderson.org

Abstract: Multiple studies have demonstrated that lncRNAs extensively participate in human cancer proliferation and metastasis. Epigenetic modification, transcriptional and posttranscriptional regulatory mechanisms are involved in lncRNA-led tumorigenesis and transfer. Recently, a novel identified homeobox (HOX) A11 antisense lncRNA, *HOXA11-AS*, 1,628 bp in length, has been excessively highlighted to be an essential initiator and facilitator in the process of malignant tumor proliferation and metastasis. As found in many reports, *HOXA11-AS* can not only act as a molecular scaffold of PRC2, LSD1 and DNMT1 to epigenetically modify chromosomes in the nucleus but also occur as ceRNA competitively sponging miRNAs in the cytoplasm. Furthermore, *HOXA11-AS* may function as a potential biomarker for cancer diagnosis and prognosis. In this review, we summarize the evolvement and mechanisms of *HOXA11-AS* in proliferation and metastasis of various human cancers.

Keywords: *HOXA11-AS*, proliferation, metastasis, EMT, ceRNA, lncRNA, molecular scaffold

Introduction

Cell growth and aberrant proliferation is the inducer of tumor occurrence and development. Metastasis is the continuation and deterioration of cancer cell proliferation and is recognized as the most terrible feature of advanced malignant neoplasm and the major cause of death in cancer patients. Obviously, the process of tumor metastasis is extremely complicated, which contains a series of metastatic cascade.^{1,2} The tumor cells initially fall off from the primary site, then experience local infiltration, vascular invasion, blood circulation, and survival, arrest in capillaries of distant organs, colonization starts and growth is renewed.^{3,4} A large body of genes and their products have been reported to mediate metastatic initiation and progression, such as adhesion molecules, angiogenic factors, matrix metalloproteinases, chemokines and so on.⁵⁻⁸ More recently, miRNAs and lncRNAs also emerge to be crucial regulators in cancer proliferation and metastasis.^{9,10}

It is widely known that only 2% of the genome sequences is translated into proteins, while the remainder is the template for ncRNAs transcription.^{11,12} Compared to miRNAs, lncRNAs exert more favorable functions in tumor malignant proliferation, invasion and migration. The novel lncRNA, *HOXA11-AS*, also known as HOXA11-AS1, is the homeobox (HOX) A11 antisense lncRNA. In the human genome, the HOX family of genes is characterized by highly conserved homeodomains. HOX genes are grouped into four clusters (A, B, C and D) located on four different chromosomes. *HOXA11-AS* gene maps to the HOXA gene cluster on chromosome 7p, which includes the protein-coding genes (*HOXA9*, *HOXA10*, *HOXA11* and *HOXA13*) and the genes for lncRNAs (*HOXA10-AS*, *HOXA11-AS* and *HOTTIP*).^{13,14} As a *HOXA11*

antisense lncRNA, *HOXA11-AS* may participate in embryo implantation, endometrial development and cervix carcinogenesis by regulating *HOXA11*.^{15–17} Increasing evidences have shown that *HOXA11-AS* can be a novel regulator in the proliferation and metastasis of diverse human cancers.^{18–21}

Research identifications prove that numerous lncRNAs can serve as molecular signals, decoys, guides and scaffolds, exerting their functional roles via epigenetic modification or transcriptional activation/suppression in the nucleus. For instance, lncRNA *GCInc1* promotes gastric tumorigenesis, invasiveness and metastasis by acting as a modular scaffold of WDR5 and KAT2A complexes and specifying the histone modification pattern on the target genes.²² The lncRNA *MALAT1* can be a molecular decoy through binding to SFPQ and releasing the oncogene PTBP2 from SFPQ/PTBP2 complex, thus accelerating colorectal cancer (CRC) growth and metastasis.²³ In addition, lncRNAs also emerge as ceRNAs by sponging microRNAs, and sometimes bind with specific proteins to maintain mRNA stability or induce mRNA decay, thus participating in posttranscriptional processing in the cytoplasm.^{24–26} Dramatically, *HOXA11-AS* can regulate human cancer cell growth and metastasis both transcriptionally and posttranscriptionally and turn to be cancer biomarkers and therapeutic targets.

In our review, we will summarize the biological functions, molecular mechanisms and clinical significance of *HOXA11-AS* in diverse human cancers.

***HOXA11-AS* in diverse human cancers**

Non-small-cell lung cancer (NSCLC)

NSCLC accounts for ~80%–85% of lung cancer.²⁷ The survival rate of advanced NSCLC patients remains disappointing, which is attributed to the malignant invasion and migration in NSCLC.^{28,29} lncRNA dysregulation in NSCLC has been demonstrated as one of the leading forces during NSCLC carcinogenesis and metastasis in several studies.^{30,31} A recent study stated that no *HOXA11-AS* expression has been found in normal lung tissues.³² Four other papers published online indicated that *HOXA11-AS* is significantly upregulated in NSCLC. Zhang et al found through a high-throughput microarray assay that the downstream gene profiles changed after *HOXA11-AS* knockdown in A549 cell line. Ectopic overexpression of *HOXA11-AS* was potentially associated with DOCK8 and TGF- β pathway by The Cancer Genome Atlas database and bioinformatics analyses (Gene Ontology pathway, Kyoto Encyclopedia of Genes and Genomes and network analyses). In their other study, *HOXA11-AS* was proved to play a crucial role in

NSCLC invasion, migration and proliferation. Collectively, both these manuscripts indicated the potential diagnostic value of *HOXA11-AS* in NSCLC.^{33,34} Chen's team explored *HOXA11-AS* regulatory function in NSCLC epithelial–mesenchymal transition (EMT) process. Mechanically, *HOXA11-AS* could simultaneously interact with EZH2 and DNMT1, recruiting them to the *miR-200b* promoter regions, epigenetically repressing *miR-200b* expression.¹⁸ Lastly, *HOXA11-AS* was also confirmed to be a ceRNA sponging for *miR-124* to regulate Sp1 expression, thus promoting NSCLC cell proliferation and invasion.³⁵ Collectively, these findings implicate that *HOXA11-AS* occurs as an oncogene promoting NSCLC growth and metastasis, and may be a pivotal target for NSCLC diagnosis and therapy.

Gastric cancer (GC)

In China, GC ranks second with high rates of morbidity and mortality, among all cancers.³⁶ The GC cells easily transfer and spread in spite of radical surgery or adjuvant chemotherapy; disappointingly, nearly 60% of postoperative patients show recurrence or metastasis.^{37,38} Recently, we screened a GC-associated lncRNA *HOXA11-AS* through The Cancer Genome Atlas RNA sequencing data and other available microarray online data. *HOXA11-AS* was found to be significantly upregulated in human GC tissues, which predicts a terrible prognosis in GC patients with a high expression. Apparently, cell growth, migration and invasion were involved in *HOXA11-AS*-mediated GC cell phenotypes. Multilevel research revealed that *HOXA11-AS* was triggered by transcription factor E2F1 and emerged as a molecular scaffold of EZH2/LSD1/DNMT1 in GC cell nucleus. On the other side, *HOXA11-AS* occurred as a ceRNA sponging for *miR-1297*, antagonizing its ability to repress EZH2 protein translation.³⁹ On the basis of the above study, we further investigated by RNA immunoprecipitation analysis and found that *HOXA11-AS* could also bind with WDR5 and STAU1 in GC cells. Subsequently, *HOXA11-AS*-WDR5 was confirmed to promote β -catenin expression, *HOXA11-AS*-EZH2 could epigenetically silence *P21* expression, and *HOXA11-AS*-STAU1 was determined to induce *KLF2* mRNA degradation in GC cell cytoplasm.¹⁹ In conclusion, our findings show that *HOXA11-AS* plays its carcinogenic regulatory role both transcriptionally and posttranscriptionally in GC.

CRC

CRC is another common gastrointestinal carcinoma and the fourth leading cause of cancer death around the world.^{40,41} The key to treatment and prognosis is early detection, timely

diagnosis and radical surgery. Unfortunately, it is already in an advanced stage when CRC is confirmed in a patient.⁴² Recently, lncRNA *HOXA11-AS* has been reported as a tumor-suppressor gene or an oncogene in two independent CRC-relevant papers. In the first manuscript, the author found that *HOXA11-AS* was decreased in CRC tissues and cell lines. Clinicopathologic analysis further proved that *HOXA11-AS* downregulation was significantly related with CRC patients' tumor size, lymph node metastasis, TNM stage and carcino-embryonic antigen level, which indicated *HOXA11-AS* to be a tumor-suppressor gene in CRC.⁴³ Inversely, in Chen et al's study, *HOXA11-AS* was verified as a highly related oncogene to liver metastasis in CRC. In more detail, *HOXA11-AS* was significantly upregulated in 15 patients with liver metastasis and highly invasive cell lines; gain-/loss-of-function studies showed that *HOXA11-AS* promoted CRC cell migration and invasion; *HOXA11-AS* also functioned as an *miR-125a-5p* sponge ceRNA and indirectly influenced the expression levels of *PADI2*.²⁰ The different conclusions of these two studies may be attributed to the differences in the patients' samples collected and the selected cell types. In my opinion, *HOXA11-AS* overexpression in metastatic CRC and its downregulation in general/unassorted CRC including their separate functions should be further validated by more researchers.

Glioma

Glioma is one of the most common primary neoplasms in the central nervous system, accounting for nearly 50% of all intracranial primary tumors.⁴⁴ Recently, several studies have emphasized the important role of lncRNA *HOXA11-AS* in regulating glioma tumorigenesis and transfer. Xu et al demonstrated that *HOXA11-AS* overexpression promoted glioma cell growth and metastasis through serving as a ceRNA for *miR-214-3 p*.⁴⁵ Similarly, Cui et al's study also proved *HOXA11-AS* to be a ceRNA sponging *miR-140-5 p* in the process of glioma cell proliferation.⁴⁶ In addition, another paper published in *Cancer Lett* showed that *HOXA11-AS* acted as an oncogene in cell cycle progression in a series of bioinformatic analysis.⁴⁷ Statistically, these manuscripts together found that high expression of *HOXA11-AS* was closely correlated with shorter overall survival and poorer prognosis in patients with glioma, which suggests that *HOXA11-AS* is an effective prognostic marker in glioma patients.

Cervical cancer (CC)

CC is one of the most common gynecologic cancers, clinically due to persistent infection with human papilloma

viruses.⁴⁸ In the recent 2 years, the rising star *HOXA11-AS* was demonstrated to be closely connected with CC proliferation, invasion, migration and patients' prognosis. Chen et al discovered CC-associated lncRNA *HOXA11-AS* by performing lncRNA microarray of three cervix cancer and normal cervix tissues. Furthermore, they found that *HOXA11-AS* regulated *HOXA11* expression in cervix carcinogenesis.¹⁷ Besides, another team proved that overexpression of *HOXA11-AS* in CC was exactly relevant to EMT process by regulating EMT-related genes (*E-cadherin*, *β-catenin*, *Vimentin* and *Snail*). Noticeably, *HOXA11-AS* could promote sphere formation and maintain stemness in CC, which may contribute to CC cell proliferation, metastasis and recurrence.⁴⁹

Breast cancer (BC)

BC has become one of the most frequent malignancies in women.⁵⁰ Obviously, distant metastasis is the leading cause of deterioration in BC patients.⁵¹ Li et al lately found lncRNA *HOXA11-AS* to be an inducer in BC EMT process. *HOXA11-AS* was found to be highly expressed in BC tissue and cells. The functional experiments in vitro and in vivo manifested that *HOXA11-AS* knockdown could inhibit BC cell proliferation, invasion and migration. Interestingly, *HOXA11-AS* was involved in the EMT process by affecting the expression levels of *E-cadherin*, N-cadherin and *Vimentin*.²¹

Epithelial ovarian cancer (EOC)

EOC accounts for nearly 90% of all human ovarian tumors.⁵² A recent study found a functional genetic variant in *HOXA11-AS* that could suppress EOC oncogenic phenotype. Firstly, the author discovered from genome-wide association study that *HOXA11-AS* SNP rs17427875 (A>T) could reduce the risk for serous EOC. Subsequently, transfection assays in vitro and in vivo suggested that *HOXA11-AS* rs17427875 minor allele inhibits EOC cell survival, migration and invasion.⁵³ This research provides a new insight for the regulatory effect of lncRNA genetic variant in cancer development.

Hepatocellular carcinoma (HCC)

Previous studies proved that hepatitis C and B virus infection, excessive drinking, toxins and other auxotrophic liver diseases were involved as the leading causes of HCC.^{54,55} Lately, lncRNA-cancer-associated researches have pointed out that plenty of lncRNAs also participate in HCC progression.⁵⁶ As expected, *HOXA11-AS* was proved to be highly expressed in HCC tissues and cells. Functional

experiments demonstrated that *HOXA11-AS* promoted HCC proliferation through regulating cell apoptosis and cell cycle progression. Mechanistically, *HOXA11-AS* could bind with EZH2 to epigenetically inhibit *LATS1* expression.⁵⁷ Also, Liu et al proved that *HOXA11-AS* could also recruit EZH2 to *DUSP5*'s promoter region and restrain the transcription of *DUSP5*.⁵⁸

Uveal melanoma (UM)

UM ranks first in morbidity among intraocular tumors abroad and is second only to retinoblastoma in China. This malignancy is easily transferred and 85% is transferred to the liver.^{59,60} Lu et al found that *HOXA11-AS* was upregulated in UM and could be an oncogene in UM malignant phenotype. Mechanistically, *HOXA11-AS* could not only bind with EZH2 to repress *P21* transcription but also sponge for *miR-124* simultaneously.⁶¹

Osteosarcoma (OS)

OS is the most common malignant primary bone tumor, which is characterized by the formation of neoplastic bone-like tissue. Pulmonary metastasis occurs within just a few months, and the survival rate is only 5%–20% after amputation.⁶² The lncRNA *HOXA11-AS* was confirmed to be over-expressed in OS tissues and cells. *HOXA11-AS* upregulation was closely associated with cell proliferation and invasion. Moreover, *HOXA11-AS* could function as a ceRNA regulating *ROCK1* expression via sponging *miR-124-3 p* in OS. Clinically, high expression of *HOXA11-AS* was related to OS patients' advanced stage, distant metastasis and poor prognosis.⁶³

HOXA11-AS can be a potential biomarker for cancer diagnosis and prognosis

Aforementioned reports prove that *HOXA11-AS* expression levels in majority of tumors are increased. Table 1 summarizes the *HOXA11-AS*-associated clinicopathologic features,

such as patients' tumor size, TNM stage and lymph node metastasis, which emphasizes the evolvement of *HOXA11-AS* in human cancer diagnosis. As shown in Table 1, aberrant expression of *HOXA11-AS* is also implicated as a prognostic biomarker in different cancer types. In particular, Li et al⁶⁴ and Mu et al⁶⁵ separately conducted a meta-analysis exploring *HOXA11-AS* to be a potential biomarker for metastasis and patients' prognosis in malignancies.

Discussion

Malignant proliferation of cancer cells and metastasis propel the progression of carcinoma deterioration. Separately, cancer metastasis is a complicated multistep process that often contributes to patients' postoperative recurrence and poor prognosis. Recent theoretical and practical research states that EMT can elucidate partial reasons for cancer invasion and dissemination. The entire EMT process includes loss of epithelial cell characteristics and acquisition of mesenchymal characteristics. During this transformation, the mesenchymal markers increase, including *Snail*, *Slug*, *N-cadherin* and *Vimentin*. On the contrary, decreased *E-cadherin* is the most common epithelial marker in EMT.^{66,67} Noticeably, EMT course is exactly included in partial *HOXA11-AS*-modulated metastasis of cancers such as NSCLC, CC, and BC. The expression levels of several canonical EMT molecular markers, *E-cadherin*, *N-cadherin*, *Snail*, β -*catenin* and *Vimentin*, were changed after loss of or gain of *HOXA11-AS*. The functional characteristics of *HOXA11-AS* in various human cancers are all summarized in Table 2.

The ceRNA theory serves as a posttranscriptional way, which can explain the regulatory mode of lncRNA–miRNA–mRNA. The lncRNAs function as ceRNAs sponging for miRNAs, thus affecting the expression levels of miRNAs target genes.^{68,69} As expected, *HOXA11-AS* can sponge for various miRNAs in different cancers (Table 2). Certainly, apart from ceRNA-modulatory pattern, *HOXA11-AS* simultaneously interacts with EZH2/LSD1/DNMT1, epigenetically modifying the target genes in cancer.

Table 1 *HOXA11-AS* expression levels are associated with clinicopathologic features

Cancer types	Clinicopathologic features	References
Non-small-cell lung cancer	TNM stage, lymph node metastasis, poor prognosis, high diagnostic value	18, 33–35
Gastric cancer	Short survival, poor prognosis	39
Colorectal cancer	Diagnostic value, TNM stage, lymphatic metastasis, tumor size, CEA level	43
Glioma	Glioma grade, short survival, poor prognosis	45–47
Cervical cancer	TNM stage, nodal metastasis, poor prognosis	49
EOC	Reduced serous EOC risk	53
Osteosarcoma	Advanced clinical stage, distant metastasis, poor overall survival	63

Abbreviations: CEA, carcinoembryonic antigen; EOC, epithelial ovarian cancer; TNM, tumor node metastasis.

Table 2 The functional characteristics of *HOXA11-AS* in various human cancers

Cancer types	Functional effects	Related genes	Role	References
Non-small-cell lung cancer	Migration, invasion EMT process Proliferation Apoptosis Cell cycle	DOCK8, RSPO3, DMBT1, ADAMTS8, ZEB1, ZEB2, <i>Snail</i> , <i>E-cadherin</i> , <i>N-cadherin</i> , <i>miR-200b</i> <i>miR-124</i> , <i>Sp1</i>	Oncogene	18, 33–35
Gastric cancer	Migration, invasion Proliferation Cell cycle Apoptosis	PRSS8, <i>KLF2</i> , <i>miR-1297</i> , <i>EZH2</i> <i>P21</i> , <i>Cyclin D1</i> , <i>CDK2</i> , <i>Vimentin</i> , <i>β-catenin</i>	Oncogene	19, 39
Colorectal cancer			Tumor suppressor gene	43
	Liver metastasis	<i>miR-125a-5p</i> , <i>PADI2</i>	Oncogene	20
Glioma	Migration, invasion Proliferation Apoptosis Cell cycle	<i>miR-214-3 p</i> , <i>EZH2</i> <i>miR-140-5 p</i>	Oncogene	45–47
Cervical cancer	Migration, invasion EMT process Proliferation	<i>VEGF</i> , <i>MMP-9</i> , <i>MMP-2</i> , <i>E-cadherin</i> <i>β-catenin</i> , <i>Vimentin</i> <i>Snail</i> , <i>HOXA11</i>	Oncogene	17, 49
Breast cancer	Migration, invasion EMT process Proliferation Apoptosis Cell cycle	<i>E-cadherin</i> , <i>Vimentin</i> <i>N-cadherin</i>	Oncogene	21
Epithelial ovarian cancer	Migration, invasion Proliferation		Tumor suppressor gene	53
Hepatocellular carcinoma	Proliferation	<i>LATS1</i> , <i>DUSP5</i>	Oncogene	57, 58
Uveal melanoma	Invasion Cell growth Apoptosis	<i>P21</i> , <i>miR-124</i>	Oncogene	61
Osteosarcoma	Invasion Proliferation Cell cycle	<i>miR-124-3 p</i> , <i>ROCK1</i>	Oncogene	63

Abbreviation: EMT, epithelial–mesenchymal transition.

Besides relevant reports in tumor field, *HOXA11-AS* was also discussed to be a skin-related lncRNA, which was involved in Wnt pathways in keloids.⁷⁰ Additionally, *HOXA11-AS* was found to take part in the progression of fracture healing by sponging *miR-124-3 p*.⁷¹ Moreover, *HOXA11-AS* also plays important roles in adipocyte differentiation and endometriosis in women.^{72,73} To conclude, *HOXA11-AS* is a newly identified lncRNA in various human carcinomas and other diseases, but the functions and molecular mechanisms are still not fully characterized, which deserve to be further excavated in the future.

Acknowledgment

This work was supported by the National Natural Science Foundation of China (No 81702340).

Disclosure

The authors report no conflicts of interest in this work.

References

- Langley RR, Fidler IJ. The seed and soil hypothesis revisited – the role of tumor-stroma interactions in metastasis to different organs. *Int J Cancer*. 2011;128(11):2527–2535.
- Weidle UH, Birzele F, Kollmorgen G, Rüger R. Long non-coding RNAs and their role in metastasis. *Cancer Genomics Proteomics*. 2017;14(3):143–160.
- Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. *Nature*. 2016;529(7586):298–306.
- Steeg PS. Targeting metastasis. *Nat Rev Cancer*. 2016;16(4):201–218.
- Chiang WF, Cheng TM, Chang CC, et al. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation. *Oncogene*. 2018;37(1):116–127.
- Nguyen AT, Chia J, Ros M, et al. Organelle specific O-glycosylation drives MMP14 activation, tumor growth, and metastasis. *Cancer Cell*. 2017;32(5):639–653.
- Zhao H, Yu H, Martin TA, Teng X, Jiang WG. The role of JAM-B in cancer and cancer metastasis (Review). *Oncol Rep*. 2016; 36(1):3–9.
- Ray P, Stacer AC, Fenner J, et al. CXCL12-γ in primary tumors drives breast cancer metastasis. *Oncogene*. 2015;34(16):2043–2051.
- Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. *Nat Cell Biol*. 2013;15(6):546–554.

10. Lin C, Wang Y, Wang Y, et al. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells. *Oncogene*. 2017;36(38):5392–5406.
11. Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet*. 2011;12(12):861–874.
12. Ponting CP, Oliver PL, Reik W. Evolution and functions of long non-coding RNAs. *Cell*. 2009;136(4):629–641.
13. Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, Morgan RG. HOX genes in ovarian cancer. *J Ovarian Res*. 2011;4:16.
14. Kosaki K, Kosaki R, Suzuki T, et al. Complete mutation analysis panel of the 39 human HOX genes. *Teratology*. 2002;65(2):50–62.
15. Potter SS, Branford WW. Evolutionary conservation and tissue-specific processing of Hoxa 11 antisense transcripts. *Mamm Genome*. 1998;9(10):799–806.
16. Yu H, Lindsay J, Feng ZP, et al. Evolution of coding and non-coding genes in HOX clusters of a marsupial. *BMC Genomics*. 2012;13:251.
17. Chen J, Fu Z, Ji C, et al. Systematic gene microarray analysis of the lncRNA expression profiles in human uterine cervix carcinoma. *Biomed Pharmacother*. 2015;72:83–90.
18. Chen JH, Zhou LY, Xu S, et al. Overexpression of lncRNA HOXA11-AS promotes cell epithelial-mesenchymal transition by repressing miR-200b in non-small cell lung cancer. *Cancer Cell Int*. 2017;17:64.
19. Liu X, Chen Z, Fan R, et al. Over-expressed long noncoding RNA HOXA11-AS promotes cell cycle progression and metastasis in gastric cancer. *Mol Cancer*. 2017;16(1):82.
20. Chen D, Sun Q, Zhang L, et al. The lncRNA HOXA11-AS functions as a competing endogenous RNA to regulate PADI2 expression by sponging miR-125a-5p in liver metastasis of colorectal cancer. *Oncotarget*. 2017;8(41):70642–70652.
21. Li W, Jia G, Qu Y, et al. Long non-coding RNA (lncRNA) HOXA11-AS promotes breast cancer invasion and metastasis by regulating epithelial-mesenchymal transition. *Med Sci Monit*. 2017;23:3393–3403.
22. Sun TT, He J, Liang Q, et al. lncRNA GClncl promotes gastric carcinogenesis and may act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern. *Cancer Discov*. 2016;6(7):784–801.
23. Ji Q, Zhang L, Liu X, et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. *Br J Cancer*. 2014;111(4):736–748.
24. Liu XH, Sun M, Nie FQ, et al. lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. *Mol Cancer*. 2014;13:92.
25. Cao C, Sun J, Zhang D, et al. The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β -catenin in HCC cells. *Gastroenterology*. 2015;148(2):415–426.e18–e26.
26. Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. *Nature*. 2011;470(7333):284–288.
27. Wistuba II. Genetics of preneoplasia: lessons from lung cancer. *Curr Mol Med*. 2007;7(1):3–14.
28. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–E386.
29. Shackelford RE, Vora M, Mayhall K, Cotelingam J. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. *Genes Cancer*. 2014;5(1–2):1–14.
30. Yu T, Zhao Y, Hu Z, et al. MetaLnc9 facilitates lung cancer metastasis via a PKG1-activated AKT/mTOR pathway. *Cancer Res*. 2017;77(21):5782–5794.
31. Pan C, Yao G, Liu B, et al. Long noncoding RNA FAL1 promotes cell proliferation, invasion and epithelial-mesenchymal transition through the PTEN/AKT signaling axis in non-small cell lung cancer. *Cell Physiol Biochem*. 2017;43(1):339–352.
32. Zheng LL, Li JH, Wu J, et al. deepBase v2.0: identification, expression, evolution and function of small RNAs, lncRNAs and circular RNAs from deep-sequencing data. *Nucleic Acids Res*. 2016;44(D1):D196–D202.
33. Zhang Y, He RQ, Dang YW, et al. Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells. *Cancer Cell Int*. 2016;16:89.
34. Zhang Y, Chen WJ, Gan TQ, et al. Clinical significance and effect of lncRNA HOXA11-AS in NSCLC: a study based on bioinformatics, in vitro and in vivo verification. *Sci Rep*. 2017;7(1):5567.
35. Yu W, Peng W, Jiang H, Sha H, Li J. lncRNA HOXA11-AS promotes proliferation and invasion by targeting miR-124 in human non-small cell lung cancer cells. *Tumour Biol*. 2017;39(10):1010428317721440.
36. Chen WQ. Estimation of cancer incidence and mortality in China in 2004–2005. *Zhonghua Zhong Liu Za Zhi*. 2009;31(9):664–668.
37. Correa P. Gastric cancer: overview. *Gastroenterol Clin North Am*. 2013;42(2):211–217.
38. Roviello F, Caruso S, Neri A, Marrelli D. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. *Eur J Surg Oncol*. 2013;39(12):1309–1316.
39. Sun M, Nie F, Wang Y, et al. lncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. *Cancer Res*. 2016;76(21):6299–6310.
40. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin*. 2016;66(1):7–30.
41. Perencevich M, Stoffel EM. A multidisciplinary approach to the diagnosis and management of multiple colorectal polyps. *Gastroenterol Hepatol*. 2011;7(6):420–423.
42. Sarma EA, Kawachi I, Poole EM, et al. Social integration and survival after diagnosis of colorectal cancer. *Cancer*. 2018;124(4):833–840.
43. Li T, Xu C, Cai B, et al. Expression and clinicopathological significance of the lncRNA HOXA11-AS in colorectal cancer. *Oncol Lett*. 2016;12(5):4155–4160.
44. Mansouri A, Mansouri S, Hachem LD, et al. The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: a systematic review. *Cancer*. 2016;122(16):2469–2478.
45. Xu C, He T, Li Z, Liu H, Ding B. Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells. *Biomed Pharmacother*. 2017;95:1504–1513.
46. Cui Y, Yi L, Zhao JZ, Jiang YG. Long noncoding RNA HOXA11-AS functions as miRNA sponge to promote the glioma tumorigenesis through targeting miR-140-5p. *DNA Cell Biol*. 2017;36(10):822–828.
47. Wang Q, Zhang J, Liu Y, et al. A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. *Cancer Lett*. 2016;373(2):251–259.
48. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. *Syst Rev*. 2013;2:35.
49. Kim HJ, Eoh KJ, Kim LK, et al. The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. *Oncotarget*. 2016;7(50):83001–83016.
50. Dubey AK, Gupta U, Jain S. Breast cancer statistics and prediction methodology: a systematic review and analysis. *Asian Pac J Cancer Prev*. 2015;16(10):4237–4245.
51. Raiss H, Péron J, Tartas S, et al. Palbociclib-induced thrombotic microangiopathy in metastatic breast cancer patient surviving for 18 years: case report and review of the literature. *Clin Breast Cancer*. 2018;18(3):e263–e266.
52. Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. *Cochrane Database Syst Rev*. 2013;7(7):CD006910.

53. Richards EJ, Permeth-Wey J, Li Y, et al. A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. *Oncotarget*. 2015;6(33):34745–34757.
54. Tsochatzis EA, Meyer T, Burroughs AK. Hepatocellular carcinoma. *N Engl J Med*. 2012;366(1):92. Author reply 92–93.
55. Makarova-Rusher OV, Altekruse SF, Mcneel TS, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. *Cancer*. 2016;122(11):1757–1765.
56. Yao J, Wu L, Meng X, et al. Profiling, clinicopathological correlation and functional validation of specific long non-coding RNAs for hepatocellular carcinoma. *Mol Cancer*. 2017;16(1):164.
57. Yu J, Hong JF, Kang J, Liao LH, Li CD. Promotion of LncRNA HOXA11-AS on the proliferation of hepatocellular carcinoma by regulating the expression of LATS1. *Eur Rev Med Pharmacol Sci*. 2017;21(15):3402–3411.
58. Liu B, Li J, Liu X, et al. Long non-coding RNA HOXA11-AS promotes the proliferation HCC cells by epigenetically silencing DUSP5. *Oncotarget*. 2017;8(65):109509–109521.
59. Dogrusöz M, Jager MJ, Damato B. Uveal melanoma treatment and prognostication. *Asia Pac J Ophthalmol*. 2017;6(2):186–196.
60. Shibayama Y, Namikawa K, Sone M, et al. Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population. *Int J Clin Oncol*. 2017;22(3):577–584.
61. Lu Q, Zhao N, Zha G, et al. LncRNA HOXA11-AS exerts oncogenic functions by repressing p21 and miR-124 in uveal melanoma. *DNA Cell Biol*. 2017;36(10):837–844.
62. Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma – connecting aetiology, biology and therapy. *Nat Rev Endocrinol*. 2017;13(8):480–491.
63. Cui M, Wang J, Li Q, et al. Long non-coding RNA HOXA11-AS functions as a competing endogenous RNA to regulate ROCK1 expression by sponging miR-124-3p in osteosarcoma. *Biomed Pharmacother*. 2017;92:437–444.
64. Li N, Yang M, Shi K, Li W. Long non-coding RNA HOXA11-AS in human cancer: a meta-analysis. *Clin Chim Acta*. 2017;474:165–170.
65. Mu S, Ai L, Fan F, Sun C, Hu Y. Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis. *Cancer Cell Int*. 2018;18:1.
66. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. *Cell*. 2016;166(1):21–45.
67. Singh M, Yelle N, Venugopal C, Singh SK. EMT: mechanisms and therapeutic implications. *Pharmacol Ther*. 2018;182:80–94.
68. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell*. 2011;146(3):353–358.
69. Li H, Wang X, Wen C, et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. *Mol Cancer*. 2017;16(1):169.
70. Sun XJ, Wang Q, Guo B, Liu XY, Wang B. Identification of skin-related lncRNAs as potential biomarkers that involved in Wnt pathways in keloids. *Oncotarget*. 2017;8(21):34236–34244.
71. Wang XN, Zhang LH, Cui XD, et al. lncRNA HOXA11-AS is involved in fracture healing through regulating mir-124-3p. *Eur Rev Med Pharmacol Sci*. 2017;21(21):4771–4776.
72. Nuermairaiti N, Liu J, Liang X, et al. Effect of lncRNA HOXA11-AS1 on adipocyte differentiation in human adipose-derived stem cells. *Biochem Biophys Res Commun*. 2018;495(2):1878–1884.
73. Wang M, Hao C, Huang X, et al. Aberrant expression of lncRNA (HOXA11-AS1) and homeobox A (HOXA9, HOXA10, HOXA11, and HOXA13) genes in infertile women with endometriosis. *Reprod Sci*. 2018;25(5):654–661.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress